NEOANTIGENICITY OF RIBOFLAVIN AND LIGHT TREATED RBCS IN BABOONS

$37,143P51FY2009RRNIH

Texas Biomedical Research Institute, San Antonio TX

Investigators

Linked publications, trials & patents

Paper 38655843 Paper 36859458 Paper 35925965 Paper 35855511 Paper 34437736 Paper 34022622 Paper 33962250 Paper 33899910 Paper 33626084 Paper 32126093 Paper 31831784 Paper 31709573 Paper 31442614 Paper 31284120 Paper 31206636 Paper 31048260 Paper 30951537 Paper 30875406 Paper 30718403 Paper 30673859 Paper 30620098 Paper 30256416 Paper 30246873 Paper 30071801 Paper 30039863 Paper 29976969 Paper 29693270 Paper 29661120 Paper 29593130 Paper 29516496 Paper 29504143 Paper 29471422 Paper 29412686 Paper 29154459 Paper 29063622 Paper 28724769 Paper 28641979 Paper 28620920 Paper 28543059 Paper 28145579 Paper 27870347 Paper 27870344 Paper 27870343 Paper 27627870 Paper 27506330 Paper 27402751 Paper 27393659 Paper 27327781 Paper 27298250 Paper 27259066 Paper 27226349 Paper 27178465 Paper 27053569 Paper 27053568 Paper 26984729 Paper 26924854 Paper 26899153 Paper 26821878 Paper 26819101 Paper 26813679 Paper 26808481 Paper 26611836 Paper 26360709 Paper 26156123 Paper 26072741 Paper 26049399 Paper 25926401 Paper 25873632 Paper 25769884 Paper 25761880 Paper 25749860 Paper 25651885 Paper 25560831 Paper 25529278 Paper 25529240 Paper 25529239 Paper 25524279 Paper 25447411 Paper 25447052 Paper 25429366 Paper 25415438 Paper 25415057 Paper 25398629 Paper 25360668 Paper 25255073 Paper 25245933 Paper 25242540 Paper 25234343 Paper 25187550 Paper 25097227 Paper 24947819 Paper 24935168 Paper 24871614 Paper 24759411 Paper 24756099 Paper 24732672 Paper 24707162 Paper 24674589 Paper 24664680 Paper 24633909

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study was conducted to determine whether an immune response would be elicited to RBCs treated with the Mirasol pathogen reduction technology (MPRT) using Riboflavin and UV light. The second objective was to assess the survival and recovery of MPRT treated RBCs in baboons. Autologous RBC's either untreated or Mirasol-treated were formulated with alum adjuvant and was injected into the respective baboon donors. No antibody response to RBCs was observed either in the untreated or MPRT treated baboons. Next, untreated and MPRT treated RBCs were labeled with CR51 and infused back into the donors. Survival and recovery kinetics were quite similar in the untreated and MPRT treated baboons.

View original record on NIH RePORTER →